Anaplastic Astrocytoma - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Astrocytoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anaplastic Astrocytoma - Pipeline Review, H1 2015', provides an overview of the Anaplastic Astrocytoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Astrocytoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Astrocytoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anaplastic Astrocytoma Overview 8
Therapeutics Development 9
Pipeline Products for Anaplastic Astrocytoma - Overview 9
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 10
Anaplastic Astrocytoma - Therapeutics under Development by Companies 11
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 12
Anaplastic Astrocytoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Anaplastic Astrocytoma - Products under Development by Companies 15
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 17
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 18
Amgen Inc. 18
Boehringer Ingelheim GmbH 19
Burzynski Research Institute, Inc. 20
Cavion LLC 21
e-Therapeutics plc 22
Eli Lilly and Company 23
Millennium Pharmaceuticals, Inc. 24
Novartis AG 25
Oncovir, Inc. 26
Orbus Therapeutics, Inc. 27
Pfizer Inc. 28
Sanofi 29
Tocagen Inc. 30
TVAX Biomedical, Inc. 31
Anaplastic Astrocytoma - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
afatinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alisertib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AMG-595 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Antineoplaston Therapy - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cell Therapy for Gliomas - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Dendritic Cell Therapy for Oncology - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DNX-2401 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eflornithine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ETS-2101 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
galunisertib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
mibefradil dihydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
panobinostat - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
plerixafor - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Poly-ICLC - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Stem Cell Therapy for Glioma - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
temsirolimus - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TVI-Brain-1 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Anaplastic Astrocytoma - Recent Pipeline Updates 85
Anaplastic Astrocytoma - Dormant Projects 105
Anaplastic Astrocytoma - Discontinued Products 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H1 2015 9
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Development by Companies, H1 2015 (Contd..1) 16
Products under Investigation by Universities/Institutes, H1 2015 17
Anaplastic Astrocytoma - Pipeline by Amgen Inc., H1 2015 18
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 19
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H1 2015 20
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H1 2015 21
Anaplastic Astrocytoma - Pipeline by e-Therapeutics plc, H1 2015 22
Anaplastic Astrocytoma - Pipeline by Eli Lilly and Company, H1 2015 23
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 24
Anaplastic Astrocytoma - Pipeline by Novartis AG, H1 2015 25
Anaplastic Astrocytoma - Pipeline by Oncovir, Inc., H1 2015 26
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H1 2015 27
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H1 2015 28
Anaplastic Astrocytoma - Pipeline by Sanofi, H1 2015 29
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H1 2015 30
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Assessment by Combination Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H1 2015 85
Anaplastic Astrocytoma - Dormant Projects, H1 2015 105
Anaplastic Astrocytoma - Discontinued Products, H1 2015 106